BPC-157 does not have a dose. It has three tiny human case reports, one old ulcerative colitis program, a large pile of rat experiments, and a very large number of web pages that all say roughly 250 to 500 mcg. This page keeps those four things apart and gives every number in the source’s own units.
Quick answer: There is no established BPC-157 dose and no published human dose-finding study. The human amounts on record are milligram-scale and none used the under-the-skin injection that most online protocols describe: an 80 mg rectal enema in a 2005 ulcerative colitis trial abstract, 2 to 4 mg knee injections, a 10 mg injection into the bladder wall, and 10 then 20 mg intravenous infusions in two adults.[1][2][3][5] Online protocols mostly say 250 to 500 mcg subcutaneously once or twice daily for 4 to 8 weeks, and none of those pages ties the figure to a human study.[21][22][23][24][25][26][27][28]
Figures in this section summarize amounts and schedules reported in published research, registered trials, regulator documents or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate. A note on units: mcg and µg both mean microgram, and 1,000 mcg equals 1 mg.

Every documented BPC-157 amount at a glance
No row below is Tier 1 evidence, meaning a published controlled human trial. The best human evidence for BPC-157 is Tier 2: small uncontrolled reports, a conference abstract and registered trials. The last group of rows is what the internet repeats, labeled as Tier 6 because no original source sits behind it.
Swipe the table sideways to see every column.
| Source | Population | Route | Amount reported | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|---|
| Human reports and registered trials | ||||||
| PL 14736 phase 1, healthy volunteers (Pliva) | Healthy adult men | Rectal enema | Up to 2 mg/kg (FDA table); the abstract gives no amount | Once daily (FDA table) | 8 days (FDA table); 7-day repeat enemas (abstract) | Human clinical trial, conference abstract only, Tier 2[5][6][7] |
| PL 14736 phase 2, ulcerative colitis (Ruenzi 2005 abstract) | 53 adults randomized, mild to moderate disease | Rectal enema | 80 mg | Once daily | 2 weeks | Human clinical trial, abstract only as summarized by FDA, Tier 2[5] |
| Oral phase 1, NCT02637284 | 42 planned healthy adults, ages 18 to 35 | Oral tablets of 1 mg each | Single doses of 1, 3 or 6 tablets (1, 3 or 6 mg); then 3 tablets (3 mg) per dose | Single dose; then three times daily | 14 days in part 1b | Registered human trial, no results posted, Tier 2[4] |
| Knee pain case series (Lee and Padgett 2021) | 17 treated, 16 reached; 12 BPC-157 alone, 4 with thymosin beta-4 | Intra-articular injection | 2 cc at 2,000 mcg/mL, stated as 4 mg per injection; combination injections 2 to 4 mg | One session; 2 patients repeated | One injection; follow-up 6 months to 1 year | Human observational, Tier 2[1] |
| Interstitial cystitis pilot (Lee 2024) | 12 women, ages 39 to 76 | Injection around the inflamed bladder area during cystoscopy | 10 mg total | Single procedure | One session | Human observational, Tier 2[2] |
| Intravenous safety pilot (Lee and Burgess 2025) | 2 adults, ages 58 and 68 | IV infusion in 250 cc saline over 1 hour | 10 mg on day 1; 20 mg on day 2 | One infusion per day | 2 days, labs on day 3 | Human observational, Tier 2[3] |
| Hamstring strain phase 2, NCT07437547 | 120 planned, ages 18 to 45 | Subcutaneous | Not stated in the record | Once daily | 14 days | Registered human trial, recruiting, Tier 2[8] |
| Rotator cuff repair pilot, NCT07803250 | 30 listed (summary text says 20), after surgery | Subcutaneous, self-injected | Not stated in the record | Daily | 90 days | Registered human trial, not yet recruiting, Tier 2[9] |
| Developer and compounder documents | ||||||
| Proposed clinical dose, He et al. 2022 | None (animal paper) | Not stated | 200 µg/person/day | Per day | Not stated | Developer documentation in a published animal paper, no human data[14] |
| Dosage forms proposed by compounding nominators (FDA briefing) | Not applicable | Oral capsule, subcutaneous injection, nasal spray, rectal suppository | Capsules 250 µg, 500 µg or 1 mg; injectable 2,000 µg/mL; nasal 50 µg per spray; suppository 1 mg | Not stated | Not stated | Practitioner and compounder reported, Tier 5[5] |
| Animal research (not convertible to human amounts) | ||||||
| Rat tendon and muscle healing, Zagreb group | Rats | Intraperitoneal | 10 µg/kg, 10 ng/kg or 10 pg/kg | Once daily | Days to 72 days | Published animal research, Tier 3[10][11] |
| Online, practitioner and vendor protocols | ||||||
| Eight of 11 pages that publish a dose | Not applicable | Subcutaneous, often near the injury | 250 to 500 mcg per dose (daily totals 200 to 800 mcg; some pages go to 1,000 mcg) | 1 to 2 times daily | 4 to 8 weeks, then 2 to 4 weeks off | Community, clinic and vendor reported, Tier 6; origin unclear[21][22][23][24][25][26][27][28] |
| Oral capsule protocols | Not applicable | Oral or sublingual | 250 to 500 mcg per dose; some pages 500 to 1,000 mcg | 1 to 2 times daily, empty stomach | 4 to 8 weeks (up to 12 for gut use) | Community, clinic and vendor reported, Tier 6; origin unclear[21][23][24][26][27][28] |
| Wolverine stack protocols | Not applicable | Subcutaneous | BPC-157 250 to 500 mcg with TB-500 0.25 to 5 mg per injection | BPC-157 daily; TB-500 from daily at the low end to weekly at the high end | 4 to 12 weeks | Community and vendor reported, Tier 6; conflicting between pages[21][24][27][31] |
| Any dose-finding study | Not applicable | Not applicable | Not consistently reported | Not consistently reported | Not consistently reported | No established or reliably sourced dosing information was identified[18] |
Rows use different routes, so the amounts are not comparable with each other. “Not stated” means the abstract or registry record does not give the figure. FDA’s table lists the phase 1 enema study as 24 healthy volunteers; the 2002 conference abstract describes 32.[5][7]
Where these figures come from
The short version: the human numbers trace to a handful of identifiable papers and records, and the online numbers trace to each other.
The most-reported online protocol is 250 to 500 mcg under the skin, once or twice a day, for 4 to 8 weeks. Eight of the 11 pages I opened that publish a BPC-157 dose use that range for the main injectable protocol.[21][22][23][24][25][26][27][28] Not one ties it to a human dosing study, because none exists. A 2026 pharmaceutics review states that BPC-157 has no validated dosing regimen and no completed phase II trial.[18]
So where did 250 to 500 mcg come from? The pages disagree with each other. One clinic page credits allometric scaling, which is a method of converting a dose between species by body surface.[24] A company page says it came from “dosing patterns reported by clinicians in published interviews, conference presentations, and clinical practice guidelines” and names none, then credits allometric scaling in its FAQ.[26] A telehealth page says its range comes from user-reported protocols and vendor material.[25] That clinic page also cites “Xu et al.” for the scaling math, but the 2022 pharmacokinetics paper it means has He L as first author; Xu C wrote a different 2020 safety paper.[14][15][24]
The only published attempt at turning rat doses into a human number comes from the Chinese group that developed its own BPC-157 for wound trials. In that 2022 paper, the authors write that their “proposed clinical dose of BPC157 was 200 µg/person/day,” converted by body surface area from rat doses of 6 to 50 µg/kg.[14] That is a developer’s plan, not a human result, and it sits below the 250 to 500 mcg range.
Simple arithmetic shows how soft the whole thing is. The same rat dose of 10 µg/kg produces about 97 mcg a day on one page (a surface-area conversion for 60 kg), about 122 to 130 mcg on two others, and 600 to 1,000 mcg a day on pages that just multiply by body weight.[21][22][24][25][26] A tenfold spread from one rodent number is not a dose.
The earliest source I could find for the 250 to 500 mcg figure itself is a set of web pages dated from 2025 and 2026. Reddit and forum threads, where it very likely started, could not be opened from the research environment, so I cannot name the first post. What I can say is that the older human work used milligram amounts by other routes: Pliva’s enema trials around 2002 to 2005 and a registered oral trial in 2015.[4][5][7]
Do not count the pages as independent confirmation. Two seller and publisher pages publish nearly the same step-up (200 mcg for two weeks, 400 mcg for two weeks, then 500 or 600 mcg) with different vial math.[29][30] One page describes an oral PL 14736 phase 2 trial at 0.4 mcg and 0.4 mg for 30 days; the FDA briefing describes the PL 14736 phase 2 as an 80 mg rectal enema for two weeks, and I found no source for the oral version.[5][26] Meanwhile two sites that once published full protocols have pulled them. One removed every dose, frequency, cycle and stack figure in a September 2026 correction, and another now publishes no dosing at all.[32][33]
Animal evidence is dominated by one lab. A 2026 review estimates that more than 80 percent of published BPC-157 studies come from the University of Zagreb group led by Predrag Sikiric, by author affiliation.[18] The independent work I could identify is small: a Taiwanese cell and tendon study, the Xi’an pharmacokinetic and safety papers, a 2026 Istanbul rat study and a 2026 Ankara test on human artery rings.[13][14][15][16][17]
Detailed human data
PL 14736 in ulcerative colitis, the only program with a control group
PL 14736 is Pliva’s development name for BPC-157. The company ran a phase 1 safety study in healthy volunteers and a phase 2 trial in ulcerative colitis, both with enemas. I could find only meeting abstracts for either.[5][6][7] The phase 1 conference abstract says rectal administration was “safe and well tolerated” and gives no amounts.[6] FDA’s July 2026 briefing lists that study as up to 2 mg/kg by rectal enema once daily for 8 days in 24 healthy people.[5]
The phase 2 data survive only as a 2005 meeting abstract (Ruenzi et al.), as FDA summarizes it: 53 adults with mild to moderate ulcerative colitis randomized one to one to an 80 mg enema or placebo once daily for 2 weeks, 46 completed. The disease activity index fell by 3.2 points on BPC-157 and 1.6 on placebo, and the confidence intervals overlapped (-5.58 to -0.82 versus -3.86 to 0.67).[5] FDA judged the data inadequate to support efficacy or safety and noted the abstract’s reported difference does not match its own arithmetic. In plain English: a small trial, two weeks long, with no clear separation from placebo, never followed by a phase 3.[5][18]
The oral phase 1 that never reported
NCT02637284 registered a randomized, placebo-controlled phase 1 of oral BPC-157 tablets (1 mg each, product name PCO-02) in 42 healthy adults in Tijuana, Mexico. Part 1a gave single doses of 1, 3 or 6 tablets. Part 1b gave 3 tablets three times daily for 14 days.[4] The registry lists its status as unknown, with primary completion in February 2016 and no results posted. It is the only registered test of oral BPC-157 in people, and nothing from it has been published.[4][18]
The three published case reports
All three come from the same first author, Edwin Lee, working at private clinics (the knee and intravenous reports name Florida). None had a control group.[1][2][3]
Swipe the table sideways to see every column.
| Report | Who | What was given | What was reported | Main limits |
|---|---|---|---|---|
| Knee pain, 2021[1] | 17 patients treated, 16 reached by phone; ages 19 to 77. 12 got BPC-157 alone, 4 got BPC-157 plus thymosin beta-4 | Compounded at 2,000 mcg/mL; 2 cc (4 mg) into the joint for BPC-157 alone. Combination injections ran 2 to 4 mg BPC-157 with 3 to 6 mg thymosin beta-4. Two patients had a repeat injection | 11 of 12 BPC-157-only patients and 3 of 4 combination patients reported improvement. Among the BPC-157-only group, relief lasted 6 months to 1 year in 7, 3 to 6 months in 2, up to 3 months in 2 and 24 hours in 1. No adverse events noted | Retrospective chart review, phone survey, no objective measures, follow-up varied. The full text contains internal inconsistencies between its tables and discussion |
| Interstitial cystitis, 2024[2] | 12 women, ages 39 to 76, none helped by pentosan polysulfate | 10 mg total of pharmacy-compounded BPC-157 injected around the inflamed bladder area during one cystoscopy | 10 of 12 reported complete symptom resolution; the other 2 rated success at 80 percent. No dropouts, no adverse events reported | No control group, a condition with a large placebo response, one procedure, global self-rating |
| Intravenous safety, 2025[3] | 2 adults (58-year-old man, 68-year-old woman), both with prior IV BPC-157 | 10 mg in 250 cc saline over one hour on day 1; 20 mg in 250 cc over one hour on day 2 | No measurable change in the heart, liver, kidney, thyroid or glucose markers tested; no side effects reported | Two people, no efficacy question, one clinic. Cannot show safety for repeat dosing |
A 2026 PRISMA systematic review (PROSPERO CRD420261406325) found exactly these three studies, 30 participants in total, rated their methodological quality poor and the certainty of evidence very low.[20] An earlier systematic review found one clinical study among 36 included papers.[19]
Trials now registered
Two registered trials will use subcutaneous BPC-157 and neither record states an amount. NCT07437547 is a randomized, placebo-controlled phase 2 of daily subcutaneous injections for 14 days after an MRI-confirmed grade II hamstring strain, sponsored by Hudson Biotech, recruiting in Shenzhen since February 2026, with 120 participants planned. It excludes people subject to anti-doping testing.[8] NCT07803250 is a University of Arkansas pilot in rotator cuff repair, with daily self-injection for 90 days planned to begin in January 2027.[9]
How the published human amounts compare with the online ones
The pattern is clear. Every published or registered human exposure to BPC-157 is in milligrams per administration, from 1 mg up to 80 mg. The online subcutaneous protocols are 0.25 to 0.5 mg, below even the smallest human amount on record, and no published human report used the subcutaneous route at all. So the popular protocol has no human data behind it in either direction: no evidence it works at that amount, and none that it fails or is unsafe.
Animal research amounts
These are the amounts in the papers’ own units. They are not human doses, and nobody should convert them. Rodent amounts are given per kilogram of body weight, and the same animal figure yields very different human numbers depending on the method used (see the section on where figures come from).
Swipe the table sideways to see every column.
| Study | Model | Route | Amount (source units) | Frequency | Duration | Evidence |
|---|---|---|---|---|---|---|
| Achilles tendon transection, Staresinic 2003[10] | Rat | Intraperitoneal | 10 µg, 10 ng or 10 pg/kg | Once daily, first dose 30 minutes after surgery | Assessed to day 14 | Published animal research, Tier 3 (Zagreb) |
| Quadriceps muscle transection, Staresinic 2006[11] | Rat | Intraperitoneal | 10 µg, 10 ng or 10 pg/kg | Once daily | 72 days | Published animal research, Tier 3 (Zagreb) |
| Muscle crush injury, Novinscak 2008[12] | Rat | Intraperitoneal, or a thin layer of cream on the site | Not stated in the abstract | Once daily | 14 days | Published animal research, Tier 3 (Zagreb) |
| Colonic fistula, NSAID lesions, liver injury (as listed by FDA)[5] | Rat | Intraperitoneal or oral | 10 ng/kg or 10 µg/kg (colonic fistula: per day) | Daily | Up to 28 days | Published animal research as summarized by FDA, Tier 3 |
| Drinking-water studies (as described by two web pages)[22][24] | Rat | In drinking water | 0.16 µg/mL, about 12 mL per rat per day | Daily | Not stated | Origin unclear; primary paper not opened |
| Achilles tendon repair, Biçer 2026[13] | 32 rats, 8 per group | Intraperitoneal | 10 µg/kg/day (TB-500 arm 60 µg/kg/day) | Daily | 4 weeks | Published animal research, Tier 3 (independent, Istanbul) |
| Pharmacokinetics, He 2022[14] | Rats; beagle dogs | IV single; IM single; IM daily | Rats: IV 20 µg/kg; IM 20, 100, 500 µg/kg; repeat IM 100 µg/kg. Dogs: IV 6 µg/kg; IM 6, 30, 150 µg/kg; repeat IM 30 µg/kg | Single, or daily | Repeat dosing 7 days | Published animal research, Tier 3 (independent, Xi’an) |
| Repeat-dose toxicity (FDA table and Xu 2020)[5][15] | Rats; dogs | Intramuscular | Rats 0.2, 1.0, 4.0 mg/kg; dogs 0.1, 0.5, 2.0 mg/kg | Once daily | 28 days plus 14-day recovery | Published animal research, Tier 3 (independent, Xi’an) |
| Human internal mammary artery rings, Yildirim 2026[17] | Tissue from 12 bypass patients, in a dish | Added to tissue bath | 0.01 to 1 mg/mL cumulative | Not applicable | Not applicable | Laboratory research, Tier 4 |
The abstracts of the 2003 and 2006 papers report benefit at all three levels, 10 pg/kg to 10 µg/kg, a millionfold range. A flat response across that range leaves no usable dose-response curve to anchor a human amount.[10][11]
What the independent work found is mixed. The Xi’an papers confirm BPC-157 is cleared fast: elimination half-life 15.2 minutes in rats and 5.27 minutes in dogs, with intramuscular bioavailability of 14 to 19 percent in rats and 45 to 51 percent in dogs.[14] The dose-to-exposure relationship was linear, and 28-day toxicity studies found no serious toxicity in mice, rats, rabbits and dogs, apart from a creatinine decrease in dogs at 2 mg/kg that recovered after withdrawal.[15] The 2026 Istanbul rat study used 10 µg/kg/day for four weeks: BPC-157 alone did not produce a statistically significant change in maximum load to failure or in total tendon scores, while TB-500 did.[13] That is a small, exploratory study, but it is the cleanest independent look at the headline tendon claim.
Practitioner and community-reported protocols
This is the section most people came for. These protocols are not clinical evidence. They are what clinics, education sites and companies publish, listed with the source type so you can weigh them. I opened 11 pages that publish BPC-157 amounts. Reddit threads could not be opened from the research environment, so none is cited, and no page I opened attaches a named clinician’s own patient data to a protocol.
BPC-157 dosage chart as reported
Swipe the table sideways to see every column.
| Route | Low end reported | Most reported | High end reported | Frequency | Cycle and break |
|---|---|---|---|---|---|
| Subcutaneous | 200 to 250 mcg per dose | 250 to 500 mcg per dose; 500 mcg a day total | 750 to 1,000 mcg a day (split) | Once or twice daily | 4 to 8 weeks on, 2 to 4 weeks off; 8 to 12 weeks for chronic problems[21][22][23][24][25][27][28] |
| Oral or sublingual | 200 to 250 mcg | 250 to 500 mcg once or twice daily | 500 to 1,000 mcg per dose | Once or twice daily, empty stomach | 4 to 8 weeks (up to 12 for gut use)[21][23][24][26][27][28] |
| Intramuscular | 250 mcg | 250 to 500 mcg once daily | Not consistently reported | Once daily | 4 to 6 weeks[23][28] |
Source by source
Swipe the table sideways to see every column.
| Source and type | Route and amount | Frequency | Duration, breaks, loading | Notes on sourcing |
|---|---|---|---|---|
| Peptide Journal, education site, Dec 2025[21] | SC 200 to 800 mcg/day (500 most common). Oral 500 to 1,000 mcg/day. Sublingual 250 to 500. Says oral runs 2 to 3 times the injectable amount | Beginner 250 mcg once daily; standard 250 to 500 mcg twice daily; advanced 500 mcg twice daily near the injury | 4 to 8 weeks on, 2 to 4 off; 8 to 12 for chronic cases; 5-on 2-off optional | No author. Dosing tables not tied to a citation; two studies named in the text are missing from its reference list |
| Peptide Protocol Wiki, education site, Jan 2026[22] | SC 250 to 500 mcg per dose in the quick reference; 200 to 300 mcg and 500 mcg in the table | Twice daily in one place, once or twice in another | 4 to 6 weeks in one place, 4 to 12 in another; no break stated | Says “based on extrapolation from animal studies.” Its reference section is empty and its own tables contradict each other |
| Dr. Rogers Centers, clinic blog, Mar 2026[23] | SC 250 to 500 µg; oral or sublingual 200 to 500 µg; IM 250 to 500 µg | SC 1 to 2 times daily; IM once daily | Start 250 µg daily for 1 to 2 weeks, then up to 500 µg twice daily; 4 to 6 weeks on, 2 to 4 off; oral 6 to 8 weeks | No named author. Says ranges “reflect common practitioner-guided protocols.” Cycle length contradicts itself between sections |
| Pure Peptide Clinic, clinic editorial team reviewed by an MD, Mar 2026[24] | SC 250 to 500 mcg for acute injury; 250 mcg maintenance. Oral for gut 250 to 500 mcg; oral for systemic use 500 to 750, some to 1,000 mcg | Twice daily acute; once daily maintenance | 4 to 6 weeks (8 to 12 extended); 2 to 4 weeks off; maintenance 4 to 8 weeks | Calls its 750 to 1,000 mcg tier “practitioner-driven, not data-driven.” Credits the range to allometric scaling with a mis-attributed citation |
| TrimRx, telehealth company blog, May 2026[25] | SC 200 to 500 mcg/day; 250 mcg twice daily “probably the most frequently mentioned”; some athletes 1 mg/day or more | Daily, often split | 4 to 8 weeks on, 4 to 8 off; acute 2 to 4; chronic 8 to 12; “30 on 30 off” called convention | Says figures come from user-reported protocols and vendor material; no dosing studies named |
| PeptideMark, company education page, May 2026[26] | SC 250 to 500 mcg near (not into) the injury; oral 250 to 500 mcg for gut | Once or twice daily | 4 to 8 weeks (to 12); loading 500 mcg twice daily for 7 to 10 days then 250 mcg a day, described as having no published evidence | Credits 250 to 500 mcg to unnamed “clinician interviews” in one place and to allometric scaling in another. Contains the unsupported oral PL 14736 trial claim noted above |
| ONPEPS, peptide company blog, Jun 2026[27] | SC 200 to 500 mcg; oral 500 to 1,000 mcg per dose. Collects user reports, such as 2.5 to 3.75 mcg/kg twice daily and 0.5 mg daily for 90 days | 250 mcg twice daily most common | 2 to 4 weeks acute up to 8 to 12 chronic; 4 weeks off between cycles; “a break as long as the cycle” noted as unproven | States no universal human protocol exists; figures are observational or animal-derived |
| Swolverine, supplement retailer, Jul 2025[28] | SC or IM 250 to 500 mcg for tendon and joint; 250 to 750 for muscle; 200 to 500 for nerve; oral 250 to 500 mcg. Overall range 200 to 1,000 mcg/day | Once daily or split | 2 to 4 weeks mild, up to 6 to 8 post-op, 4 to 6 gut; no off-period required; taper example 500, then 250 mcg a day | Calls its figures anecdotal and animal-derived. Gives no reconstitution instructions |
| Biohack Labs, research-peptide seller help center, undated[29] | SC 200 mcg weeks 1 to 2, 400 mcg weeks 3 to 4, 500 mcg from week 5 | Once daily, may be split | 8 to 12 weeks (16 if continuing) | Vendor material. Its step-up schedule closely resembles the next row |
| PeptideDosages, web publisher, Mar 2026[30] | SC 200 mcg weeks 1 to 2, 400 mcg weeks 3 to 4, 600 mcg weeks 5 to 8 and beyond | Once daily | 8 to 16 week supply planning | Labels its numbers community-reported and says they are not a validated human schedule |
All of these pages describe their numbers as non-clinical. Where a page contradicts itself, both versions are shown. Pages that used to publish protocols and have since removed them are noted in the section on where figures come from.
Reconstitution examples as the sources state them
BPC-157 usually arrives as freeze-dried powder in a 5 mg or 10 mg vial. Concentration is the vial’s milligrams divided by the milliliters of water added, so the same vial can be mixed to different strengths. The pages below pick different water volumes, which is why their syringe numbers differ. U-100 insulin syringes mark 100 units per milliliter, so 10 units is 0.1 mL.
Swipe the table sideways to see every column.
| Vial | Water added | Resulting strength | Syringe example as stated | Source |
|---|---|---|---|---|
| 5 mg | 2 mL bacteriostatic water | 2.5 mg/mL (2,500 mcg/mL) | 250 mcg is 0.1 mL, or 10 units; 500 mcg is 0.2 mL, or 20 units | Peptide Journal, Pure Peptide Clinic, TrimRx[21][24][25] |
| 5 mg | 5 mL bacteriostatic water | 1 mg/mL | 250 mcg is 0.25 mL, or 25 units; 500 mcg is 0.5 mL, or 50 units | Pure Peptide Clinic[24] |
| 5 mg | 1 to 2 mL “typical” | Not stated | Not stated | Peptide Protocol Wiki[22] |
| 10 mg | 2 mL | 5 mg/mL (5,000 mcg/mL) | 10 units is 500 mcg; 5 units is 250 mcg | ONPEPS[27] |
| 10 mg | 2.5 mL | 4 mg/mL | 1 unit is 40 mcg; 5 units 200 mcg; 10 units 400 mcg; 12.5 units 500 mcg | Biohack Labs[29] |
| 10 mg | 3 mL | 3.33 mg/mL | 1 unit is about 33.3 mcg; 6 units 200 mcg; 12 units 400 mcg; 18 units 600 mcg | PeptideDosages[30] |
The only concentration used in a published human report is 2,000 mcg/mL, in the knee series, and the FDA briefing lists the same strength for a proposed injectable.[1][5] That equals 5 mg in 2.5 mL, a volume none of the examples above uses. For the step-by-step mixing and the unit math, see our guides on how much water to use and how to reconstitute a peptide, or plug your own vial into the reconstitution calculator, which starts with no preset numbers.

Escalation, timing, duration and routes
None of the following is established. This is what is reported, and what the evidence does and does not say.
Starting low and stepping up
Three pages describe a step-up. One starts at 250 mcg a day for 1 to 2 weeks and then moves to 500 mcg twice daily.[23] Two use a two-week staircase from 200 mcg to 400 mcg and then 500 or 600 mcg.[29][30] A fourth describes a “loading” week at 500 mcg twice daily and then a drop to 250 mcg a day, and says plainly that no published evidence supports loading.[26] No human study has tested any of these.
Once daily or twice daily
Twice daily is the most common split. The usual reasoning is the drug’s short life in the body: half-life under 30 minutes in rats and dogs.[14][18] But a short half-life does not tell you what schedule works, because the claimed effects in animals last hours to days after a single dose, a mismatch a 2026 review flags as a problem for dosing strategy.[18] TrimRx calls its own twice-daily split a guess without pharmacokinetic data.[25]
Where it is injected
The pages that discuss sites name the abdomen or thigh for subcutaneous use, and “near the injury” for tendon and joint problems, with a minority using intramuscular injection.[21][22][25][26][28] Two pages say outright that whether injecting near the injury beats injecting elsewhere has not been tested in humans.[25][26] Our subcutaneous injection basics guide covers the technique itself.
Oral capsules versus injection
The case for oral is real but incomplete. BPC-157 resists stomach acid and pepsin in lab tests, which most peptides do not.[18] Stability in the stomach is necessary but not enough: the gut wall and the liver still stand between a swallowed capsule and the bloodstream, and a 2026 review says human oral absorption is unknown.[18] The only registered oral human trial never reported results.[4] Several pages raise the oral amount to 2 to 3 times the injectable one to compensate, which is a guess.[21][24][27] The HHS policy treats this gap as real: oral products need documentation of adequate oral bioavailability in humans.[34] Our guide on why peptides are injected, and how oral and nasal routes differ explains the general problem.
Cycle length and breaks
The reported cycle is 4 to 8 weeks on and 2 to 4 weeks off, with 8 to 12 weeks for chronic or tendon problems and a few pages going to 13 or 16 weeks.[21][23][24][25][27][29] TrimRx says “30 on 30 off” is convention and was not derived from BPC-157 research.[25] Swolverine says no break or taper is clinically required.[28] The longest dosing period in a controlled human trial design is 14 days (the enema trial and the oral phase 1 plan), and the longest planned in a current trial is 90 days.[4][5][9]
Combinations and stacks
Formally studied. In humans, only the four-person knee subgroup that received BPC-157 with full-length thymosin beta-4, which is not the same molecule as the TB-500 sold online.[1] In animals, the 2026 Istanbul Achilles study compared BPC-157, TB-500 and both together in rats and found no added benefit from the combination over either alone.[13]
Mechanistically plausible. Reviews describe BPC-157 as acting on blood vessel growth and cell growth pathways, which is why it gets paired with other repair-oriented peptides, but that is a hypothesis about biology, not a tested combination.[19]
Practitioner reported. Pure Peptide Clinic lists a stack of BPC-157 at 250 to 500 mcg a day with TB-500 at 750 to 2,000 mcg two to three times a week during loading, then weekly, and states no published research covers dose adjustment when stacking.[24]
Community reported, the Wolverine stack. Peptide Journal lists BPC-157 250 to 500 mcg once or twice daily with TB-500 at 2 to 5 mg twice a week for loading and weekly for maintenance.[21] ONPEPS lists BPC-157 250 mcg daily with TB-500 2.5 mg on Monday and Thursday for weeks 1 to 4, then Mondays only to week 12.[27] A Substack post lists a 1:1 option at 250 mcg of each, and a high-TB-500 option at 2.0 to 2.5 mg twice weekly for 4 to 6 weeks, with a stated maximum of 90 consecutive days.[31] The schedules disagree on TB-500 by an order of magnitude or more, and none cites a source. See our Wolverine blend page and the TB-500 entry.
The popular multi-peptide blends add more unknowns. See GHK-Cu plus BPC-157, KLOW and GLOW for what each contains and what is known about the pieces. One regulatory point matters here: the HHS policy covers products with a single active ingredient, so a blend is outside it.[35][41]
Side effects, quality and sourcing risks
The honest summary is that nobody knows the side effect profile, because the human data are too thin to measure one.
- The three Lee reports recorded no adverse events across 30 people, but the knee and cystitis reports relied on recall and a global rating, and the IV report involved two people.[1][2][3][20]
- FDA’s database held three reports of injectable BPC-157 through 4 December 2025: injection-site redness and swelling lasting nine days; shortness of breath leading to an emergency visit; and skin and gum darkening in a woman using BPC-157 with TB-500, which returned when she restarted. FDA said it could not draw definitive conclusions from those reports alone, and the combination case cannot be pinned on one peptide.[5][42]
- FDA’s stated problem is missing information: insufficient clinical safety data, animal toxicology limited in scope and duration for the proposed routes, and no data on immune reactions (immunogenicity), which it called a significant risk for injected and nasal forms.[5]
- Reviews raise theoretical concerns about a peptide that promotes new blood vessel growth, including cancer risk, which has not been shown in people and remains debated.[18][40]
Quality is the other half of the risk. FDA described both forms of BPC-157, the free base and the acetate salt, as not well characterized, with inconsistent naming, certificates of analysis lacking impurity and endotoxin data, and missing particle-size and container information.[5] The HHS formula for the acetate carries a variable number of acetate groups, so a label weight can mean different things.[34] I found no peer-reviewed survey testing what is actually in gray-market BPC-157 vials, so claims about specific contamination rates online should be treated as unverified. The general hazards are the ones a 2026 review lists for unregulated injectables: contamination, manufacturing impurities and inaccurate dosing.[40] Our guide to reading a peptide COA explains what a lab report can and cannot show.
Regulatory and development status
As of 2 November 2026, BPC-157 is not an approved drug. FDA has not approved it, the EMA has issued no opinion on it, it is not on FDA’s 503A bulk drug substances list, and the newest US development is a draft HHS enforcement policy.[5][18][34][42]
Swipe the table sideways to see every column.
| When | What happened | Source |
|---|---|---|
| September 2023 | FDA placed BPC-157 (free base and acetate) in interim Category 2, the group of bulk substances flagged for possible significant safety risk. The exact day is not given in the HHS document | HHS policy[34] |
| 1 January 2026 | WADA’s 2026 Prohibited List takes effect. Its S0 class of non-approved substances, prohibited at all times, names BPC-157 (“including but not limited to BPC-157”) | WADA list[39] |
| April 2026 | BPC-157 removed from Category 2 after the original nominators withdrew their nominations. HHS records 22 April 2026; a law-firm bulletin dates FDA’s list update 15 April. Removal did not make it eligible for compounding and is not a safety finding | HHS policy; law-firm bulletin[34][38] |
| Before 23 July 2026 | FDA staff review for ulcerative colitis, the only use evaluated: data “do not support the use of BPC-157 for the treatment of UC”; staff proposed adding neither form to the bulks list | FDA briefing[5] |
| 23 July 2026 | Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 to the 503A bulks list, reported as 8 to 6 with one abstention. The vote is non-binding; outlets differ on whether the tally covered BPC-157 alone | FDA meeting page; news report[36][37] |
| 28 and 30 October 2026 | HHS released its draft enforcement discretion policy on 28 October; it was published as 91 FR 68526 on 30 October. Comments run to 13 November 2026 | HHS policy; law-firm analysis[34][35] |
What the HHS policy does: it says HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians who compound BPC-157 acetate, in subcutaneous, intramuscular, oral and topical forms, when ten conditions are met. They include an FDA-registered source with a valid certificate of analysis, the label “This is a compounded drug product. Not for resale,” one active ingredient only, adverse-event reporting, and, for oral products, documentation of adequate human oral bioavailability.[34] What it does not do: it is not an FDA approval, it does not add BPC-157 to the bulks list, which needs rulemaking, and it is described as a draft that HHS can revise.[34][35][41] Other routes people mention, such as nasal, rectal, intravenous or intravesical, are not among the listed routes. For the full walkthrough see our HHS peptide policy explainer. For a plain-language report on the same policy, see The Weight Loss Atlas report on the HHS enforcement discretion policy, and for the dated sequence of decisions, its peptide policy tracker.
For athletes, the 2026 WADA list is unambiguous. One 2026 review says WADA reversed an earlier ban; the 2026 text names BPC-157 under S0, so treat it as prohibited.[18][39]

What is not public
- Any human dose-finding study, for any route or purpose.
- Human pharmacokinetics after subcutaneous or oral dosing, and any result from the 2015 oral phase 1 (NCT02637284).[4][18]
- The amounts in the two registered subcutaneous trials, and their results.[8][9]
- Whether the original Pliva phase 2 data exist beyond a meeting abstract.[5]
- The first source of the 250 to 500 mcg figure, and which BPC-157 form (free base or acetate) any study or online protocol actually used.[5]
- Independent replication of most of the Zagreb group’s animal findings.[18]
- Long-term safety, including the theoretical cancer question.[40]
- What gray-market vials actually contain.
Frequently asked questions
What is the BPC-157 dosage?
No dose is established. The human amounts on record are an 80 mg rectal enema (a 2005 ulcerative colitis trial abstract), 2 to 4 mg injected into knees, 10 mg injected into the bladder wall, and 10 then 20 mg intravenously in two adults. Online pages mostly report 250 to 500 mcg subcutaneously once or twice daily, with no human study behind it.
Is there a BPC-157 dosage chart?
Reported ranges exist, and the chart in this page’s community section collects them: subcutaneous 250 to 500 mcg per dose, oral 250 to 500 mcg per dose, typically 4 to 8 weeks with 2 to 4 weeks off. These are what web pages say, not validated amounts, and the pages contradict each other, including about the daily total.
BPC-157 5mg vial: how much water?
Pages disagree because any volume works. Examples as stated: 2 mL of bacteriostatic water gives 2.5 mg/mL, and 5 mL gives 1 mg/mL. More water means a larger syringe volume for the same amount, and the concentration is simply the vial’s milligrams divided by the milliliters added. Our reconstitution guides and calculator show the math for any vial.
How much BPC-157 per day?
Online pages most often say 200 to 500 mcg a day under the skin, sometimes up to 1,000 mcg, as one dose or two. The only published formal calculation is a developer’s proposed 200 µg a day, from a rat-to-human conversion. No human trial tested any per-day amount subcutaneously.
How long is a BPC-157 cycle?
Most pages say 4 to 8 weeks on and 2 to 4 weeks off, with 8 to 12 weeks for chronic problems. TrimRx calls the common 30-on, 30-off pattern a convention, not something derived from BPC-157 research. The longest planned human exposure in a registered trial is 90 days.
BPC-157 oral versus injection: which is better?
Nobody knows. BPC-157 survives stomach acid in lab tests, but human oral absorption has never been measured in a published study. Websites raise the oral amount to 2 to 3 times the injectable one, which is an assumption. The HHS policy requires documentation of oral bioavailability for oral products.
What BPC-157 dosage is reported for gut, joint and tendon?
Gut: 250 to 500 mcg orally once or twice daily for 4 to 8 weeks or longer on most pages, though the only gut-related human trial used an 80 mg enema. Joint and tendon: 250 to 500 mcg subcutaneously, often near the injury, twice daily; the only joint data are 2 to 4 mg injected into the knee in a 16-patient case series. All of it is reported, not established.
Is BPC-157 legal?
It is not an approved drug. In the US it is not on the 503A bulks list. A draft HHS policy published 30 October 2026 says HHS does not intend to enforce against licensed pharmacies and physicians compounding BPC-157 acetate for subcutaneous, intramuscular, oral and topical use under ten conditions. It is prohibited for athletes under WADA’s 2026 list.
What are BPC-157 side effects?
No side effects were recorded in the three published case reports (30 people), but they cannot detect uncommon ones. FDA’s database held three injectable reports: injection-site redness and swelling, shortness of breath, and skin and gum darkening with a BPC-157 and TB-500 product. Long-term effects are unknown.
What is the Wolverine stack dose?
Community pages give BPC-157 at 250 to 500 mcg daily with TB-500 anywhere from 0.25 mg to 5 mg per injection, from about daily down to weekly, and they do not agree with each other. No human study tested the combination at these amounts, and a 2026 rat study found no added benefit from combining them.
Bottom line
BPC-157 is interesting because decades of mostly one lab’s rat studies report protection and healing across many tissues, and because it survives stomach acid. What is genuinely published in humans is three small uncontrolled case reports (knee, bladder, IV) and a 2005 ulcerative colitis abstract, all at milligram amounts by non-subcutaneous routes. What is merely reported online is 250 to 500 mcg under the skin for 4 to 8 weeks, with no original source and inconsistent details even within single pages. What remains speculative is every efficacy claim, the oral route, the best schedule and long-term safety. BPC-157 is not an approved drug. A draft US policy lets licensed compounders supply the acetate under conditions, and an advisory committee voted to recommend it against the advice of FDA staff.
Keep reading
Sources
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021 Jul. https://pubmed.ncbi.nlm.nih.gov/34324435/ Human observational (Tier 2). Retrospective chart review, one clinic. PMID 34324435. Dose details read in the full text, copy at asipp.org.
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024 Oct. https://pubmed.ncbi.nlm.nih.gov/39325560/ Human observational (Tier 2). Uncontrolled pilot. PMID 39325560.
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025 Sep. https://pubmed.ncbi.nlm.nih.gov/40131143/ Human observational (Tier 2). Two participants. PMID 40131143.
- ClinicalTrials.gov. NCT02637284: Phase I pilot study in healthy volunteers to assess the safety and pharmacokinetics of PCO-02, whose active ingredient is BPC-157. Sponsor: PharmaCotherapia d.o.o. https://clinicaltrials.gov/study/NCT02637284 Registered human trial (Tier 2 as a record). Status unknown; no results posted.
- U.S. Food and Drug Administration. BPC-157 briefing document, Pharmacy Compounding Advisory Committee, 23 July 2026. https://www.fda.gov/media/193343/download Regulator document (primary). Source here for the Ruenzi 2005 abstract summary, the human exposure table, FAERS reports, nonclinical dose levels, proposed dosage forms and FDA staff conclusions.
- Veljaca M, Pavic-Sladoljev D, Mildner B, et al. Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Eur J Pharm Sci. 2002;17:74-75 (10th United European Gastroenterology Week poster abstract). https://www.bib.irb.hr/120878 Human clinical trial, conference abstract only (Tier 2). No amounts given.
- Veljaca M, Krnic Z, Brajsa K, et al. The development of PL 14736 for treatment of inflammatory bowel disease. IUPHAR GI meeting, Honolulu, 13 to 15 July 2002, poster O-32. https://www.bib.irb.hr/192824 Conference abstract (Tier 2 and Tier 3 content). Reports a 32-volunteer phase 1 and a phase 2 that had just started.
- ClinicalTrials.gov. NCT07437547: Randomized, double-blind, placebo-controlled phase 2 trial of pentadecapeptide BPC 157 for accelerated repair of acute grade II hamstring strain confirmed by MRI (BPC-HAMSTR). Sponsor: Hudson Biotech. https://clinicaltrials.gov/study/NCT07437547 Registered human trial (Tier 2 as a record). Recruiting; amount not stated.
- ClinicalTrials.gov. NCT07803250: Impact of BPC-157 on recovery from rotator cuff repair surgery. Sponsor: University of Arkansas. https://clinicaltrials.gov/study/NCT07803250 Registered human trial (Tier 2 as a record). Not yet recruiting; amount not stated.
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://doi.org/10.1016/S0736-0266(03)00110-4 Published animal research (Tier 3). Zagreb group. PMID 14554208.
- Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):1109-1117. https://doi.org/10.1002/jor.20089 Published animal research (Tier 3). Zagreb group. PMID 16609979.
- Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-725. https://doi.org/10.1007/s00595-007-3706-2 Published animal research (Tier 3). Zagreb group. PMID 18668315.
- Bicer O, Adanir O, Guleryuz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. https://doi.org/10.52312/jdrs.2026.2951 Published animal research (Tier 3). Independent group, Istanbul. Eight rats per group. PMID 42542926.
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://doi.org/10.3389/fphar.2022.1026182 Published animal research (Tier 3) and developer document. Independent group, Xi’an. PMID 36588717, PMC9794587.
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. https://doi.org/10.1016/j.yrtph.2020.104665 Published animal research (Tier 3). Independent group, Xi’an. PMID 32334036.
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780 (online 28 October 2010). https://doi.org/10.1152/japplphysiol.00945.2010 Laboratory and cell research (Tier 4). Independent group, Taiwan. PMID 21030672.
- Yildirim AK, et al. Endothelium-dependent nitric oxide-mediated vasorelaxant effects of BPC 157 in human internal mammary artery. J Clin Med. 2026;15(9):3488. https://doi.org/10.3390/jcm15093488 Laboratory research on human tissue (Tier 4). Independent group, Ankara. PMID 42123221.
- Mateescu DM, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026;18(5):625. Published 20 May 2026. https://doi.org/10.3390/pharmaceutics18050625 Narrative review (expert commentary). Source of the more-than-80-percent single-group estimate. PMID 42198317.
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025 (online 31 July 2025). https://doi.org/10.1177/15563316251355551 Systematic review. 36 studies, 35 preclinical and 1 clinical. PMID 40756949.
- Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026 (8 October 2026). https://doi.org/10.52628/92.3.15837 Systematic review (PROSPERO CRD420261406325). Three human studies, n=30. PMID 42885452.
- Peptide Journal. How to use BPC-157: routes, dosing, and protocols. No author listed; published 13 December 2025. https://peptidejournal.org/how-to/how-to-use-bpc-157-routes-dosing-and-protocols Community and education site (Tier 6). Dosing figures not tied to citations.
- Peptide Protocol Wiki. BPC-157: dosing protocols. Page dated 29 January 2026. https://www.peptideprotocolwiki.com/peptides/bpc-157/dosing Community and education site (Tier 6). Empty reference section; internally inconsistent.
- Dr. Rogers Centers. BPC-157 dosage: a complete guide. Clinic blog, no author named; 13 March 2026. https://drrogerscenters.com/blogs/news/bpc-157-dosage-a-complete-guide Clinic reported (Tier 6).
- Pure Peptide Clinic. BPC-157 dosing guide: protocols, timing, and what the research shows. Editorial team, reviewed by an MD; 10 March 2026. https://purepeptideclinic.com/guides/bpc-157-dosing/ Clinic reported (Tier 6). Practitioner statement that upper tiers are not data-driven.
- TrimRx. BPC-157 dosing protocol: cycling, frequency and best practices. No author named; published 12 May 2026. https://trimrx.com/blog/?p=89181 Company blog (Tier 6). Says figures come from user reports and vendor material.
- PeptideMark Research Team. BPC-157 dosage: protocols and evidence guide. Published 17 May 2026. https://www.peptidemark.com/learn/bpc-157-dosage-guide-protocols-evidence Company education page (Tier 6). Contains a PL 14736 trial description that conflicts with FDA’s briefing.
- Sinha Roy A. The complete BPC-157 dosage guide: protocols, frequency, and cycle length. ONPEPS blog; published 10 June 2026. https://www.onpeps.com/blog/complete-bpc-157-dosage-protocol-cycle Company blog compiling user reports (Tier 6).
- Swolverine. BPC-157 dosage guide: how much should you take for recovery and injury healing? Supplement retailer blog; 13 July 2025. https://swolverine.com/es-gb/blogs/blog/bpc-157-dosage-guide-how-much-should-you-take-for-recovery-and-injury-healing Retailer reported (Tier 6).
- Biohack Labs. BPC-157 10mg dosage guide. Help-center article, undated. https://intercom.help/bio-hack-lab-help-center/en/articles/13835727-bpc-157-10mg-dosage-guide Seller reported (Tier 6).
- PeptideDosages Editorial Team. BPC-157 dosage guide and protocol: 10 mg vial chart. Published 1 March 2026, revised September 2026. https://peptidedosages.com/single-peptide-dosages/bpc-157-10-mg-vial-dosage-protocol/ Community reported (Tier 6). Page labels its numbers community-reported.
- Pruski D. The Wolverine stack: your complete guide to BPC-157 and TB-500 for injury healing. Research Radar (Substack); 27 January 2026. https://derekpruski.substack.com/p/the-wolverine-stack-your-complete Community reported (Tier 6). No sources cited for any dosing figure.
- FormBlends Editorial Research. BPC-157 dosage chart: research ranges and conversion math. Published 18 January 2026; corrected in September 2026 to remove all dose, frequency, cycle and stack figures. https://formblends.com/articles/peptide-hub/bpc-157-dosage-guide-complete-guide Company page (Tier 6). Cited only for the removal of its protocols.
- JumpstartMD (Sean Bourke, MD). BPC-157: evidence, safety and FDA status. Clinic page, October 2026. https://jumpstartmd.com/hub/peptide-therapy/bpc-157 Clinic page (Tier 6). States it deliberately gives no dosing protocol.
- U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. October 2026; Federal Register notice 91 FR 68526, 30 October 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf Government policy document (primary). A draft; not an approval.
- Foley & Lardner LLP. Peptides: HHS announces limited enforcement discretion for compounding of six peptides. 30 October 2026. https://www.foley.com/?p=130749 Law-firm analysis (interpretation, not a primary source).
- U.S. Food and Drug Administration. July 23 to 24, 2026: meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 Government meeting page (primary). Lists BPC-157 for ulcerative colitis on 23 July; no minutes posted when read.
- Good Morning America (ABC News). Report on the 23 July 2026 FDA advisory committee vote on BPC-157. https://goodmorningamerica.com/news/story/fda-advisory-committee-votes-add-popular-peptide-bpc-134913891 News report. Source for the 8 to 6 vote with one abstention; official minutes not checked.
- DJ Holt Law. Regulatory alert: FDA’s April 2026 update on BPC-157 and GHK-Cu. https://djholtlaw.com/regulatory-alert-fdas-april-2026-update-on-bpc-157-and-ghk-cu/ Law-firm marketing bulletin. Source for the 15 April 2026 list-update date; HHS Appendix B gives 22 April.
- World Anti-Doping Agency. The 2026 Prohibited List, effective 1 January 2026 (copy hosted by a national federation). https://www.segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf Government and sport-body rules (primary), read via a hosted copy.
- Moiz A, et al. Dangers of injectable peptides and other unregulated “biohacking” drugs. Mo Med. 2026. https://pubmed.ncbi.nlm.nih.gov/42757290/ Narrative review. PMID 42757290.
- The FDA Law Blog. The PEPTIDE-L wave reaches HHS. October 2026. https://www.thefdalawblog.com/?p=16231 Law-firm blog analysis (interpretation). Source for the single-ingredient condition and substance-by-substance scope.
- Runbeck S. Are there BPC-157 human trials? Scriptura Health blog; 22 October 2026. https://www.scriptura.health/blog/bpc-157-human-evidence-pcac-peptides Company education page. Used for FAERS dates and the bulks-list status as of 19 October 2026.
Educational reference only, not medical advice. This page documents amounts reported in research, regulator documents and online sources. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.